AU2012231814B2 - Treatment of solid tumours - Google Patents

Treatment of solid tumours Download PDF

Info

Publication number
AU2012231814B2
AU2012231814B2 AU2012231814A AU2012231814A AU2012231814B2 AU 2012231814 B2 AU2012231814 B2 AU 2012231814B2 AU 2012231814 A AU2012231814 A AU 2012231814A AU 2012231814 A AU2012231814 A AU 2012231814A AU 2012231814 B2 AU2012231814 B2 AU 2012231814B2
Authority
AU
Australia
Prior art keywords
methyl
composition
cells
compound
autophagy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012231814A
Other languages
English (en)
Other versions
AU2012231814A1 (en
Inventor
Marten Fryknas
Rolf Larsson
Stig Linder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vivolux AB
Original Assignee
Vivolux AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vivolux AB filed Critical Vivolux AB
Publication of AU2012231814A1 publication Critical patent/AU2012231814A1/en
Application granted granted Critical
Publication of AU2012231814B2 publication Critical patent/AU2012231814B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2012231814A 2011-03-21 2012-03-14 Treatment of solid tumours Active AU2012231814B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1100201-1 2011-03-21
SE1100201 2011-03-21
PCT/SE2012/000034 WO2012128689A1 (en) 2011-03-21 2012-03-14 Treatment of solid tumours

Publications (2)

Publication Number Publication Date
AU2012231814A1 AU2012231814A1 (en) 2013-09-26
AU2012231814B2 true AU2012231814B2 (en) 2016-06-09

Family

ID=46879602

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012231814A Active AU2012231814B2 (en) 2011-03-21 2012-03-14 Treatment of solid tumours

Country Status (20)

Country Link
US (2) US20140073645A1 (enExample)
EP (1) EP2688569B1 (enExample)
JP (1) JP6064215B2 (enExample)
KR (1) KR101937279B1 (enExample)
CN (1) CN103547268B (enExample)
AU (1) AU2012231814B2 (enExample)
BR (1) BR112013024211B1 (enExample)
CA (1) CA2830081C (enExample)
DK (1) DK2688569T3 (enExample)
EA (1) EA025180B1 (enExample)
ES (1) ES2681703T3 (enExample)
HU (1) HUE039021T2 (enExample)
IL (1) IL228411A (enExample)
MX (1) MX2013010770A (enExample)
PL (1) PL2688569T3 (enExample)
PT (1) PT2688569T (enExample)
SG (2) SG10201605083SA (enExample)
TR (1) TR201809040T4 (enExample)
WO (1) WO2012128689A1 (enExample)
ZA (1) ZA201307036B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2900667T3 (da) 2012-09-21 2019-08-26 Vivolux Ab Middel og fremgangsmåde til behandling af faste tumorer
US12383518B2 (en) 2013-11-03 2025-08-12 Arizona Board Of Regents On Behalf Of The University Of Arizona Disulfide-masked pro-chelator compositions and methods of use
US11504346B2 (en) 2013-11-03 2022-11-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Redox-activated pro-chelators
CN105807976B (zh) 2014-12-31 2019-02-12 清华大学 静电传感器
KR20180006916A (ko) * 2015-04-17 2018-01-19 메모리얼 슬로안-케터링 캔서 센터 고형 종양에 대한 면역치료제로서 mva 또는 mva델타e3l의 용도
CN104997777A (zh) * 2015-07-24 2015-10-28 孔小乐 去铁酮的2比1锌络合物作为制备抗癌药物的应用
JP7103745B2 (ja) * 2015-10-05 2022-07-20 国立大学法人 岡山大学 癌幹細胞抑制剤、癌の転移又は再発の抑制剤並びに癌細胞の未分化マーカー発現抑制剤
PT3390403T (pt) 2015-12-18 2022-09-06 Vivolux Ab Composição farmacêutica compreendendo derivados de indole, processo para preparação e uso dos mesmos
EP3558282A4 (en) * 2016-12-21 2020-08-12 The Medical College of Wisconsin, Inc. SYNERGIC INHIBITION OF TUMOR CELL PROLIFERATION INDUCED BY A THERAPEUTIC ASSOCIATION OF METFORMIN COMPOUNDS AND IRON CHELATORS
KR101859922B1 (ko) * 2017-02-07 2018-05-21 주식회사 온코크로스 클로페네신을 포함하는 대장암 증식 및 전이 억제용 조성물
JP6900067B2 (ja) * 2017-02-07 2021-07-07 オンコクロス カンパニー，リミテッド 癌の転移抑制および治療用組成物
CN106831776B (zh) * 2017-03-16 2018-12-07 河北科技大学 5,10-二氢吡啶并吡嗪并三嗪类化合物及其应用
US11931349B2 (en) * 2017-11-23 2024-03-19 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Iron chelators in tumor therapy
CN109646679A (zh) * 2019-01-28 2019-04-19 中国科学院长春应用化学研究所 铁离子螯合剂及其可药用盐的用途
CN110585194A (zh) * 2019-10-12 2019-12-20 广州医科大学附属第五医院 倍半萜内酯类化合物在制备溶酶体自噬抑制剂以及抗癌药物中的应用
CA3177830A1 (en) 2020-05-13 2021-11-18 Maria BECONI Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
CN111849873A (zh) * 2020-07-30 2020-10-30 扬州大学 一种诱导鸡的胚胎干细胞自噬的方法
WO2025263876A1 (ko) 2024-06-17 2025-12-26 서울대학교산학협력단 Vlx600을 포함하는 항균 또는 항진균용 조성물 및 세균 또는 진균 감염증의 예방 또는 치료용 약학적 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002089809A1 (en) * 2001-05-04 2002-11-14 The Procter & Gamble Company Medicinal uses of hydrazones and hydrazines
WO2007128820A1 (en) * 2006-05-09 2007-11-15 Novartis Ag Combination comprising an iron chelator and an anti-neoplastic agent and use thereof
WO2009035534A2 (en) * 2007-09-07 2009-03-19 The Cleveland Clinic Foundation Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1335686C (fr) * 1986-01-13 1995-05-23 Rao K. S. P. Bhushana Vinblastine et composition pharmaceutique les contenant
US5480906A (en) * 1994-07-01 1996-01-02 Eli Lilly And Company Stereochemical Wortmannin derivatives
IL121272A (en) * 1997-07-10 2000-06-01 Can Fite Technologies Ltd Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia
DE602004031095D1 (de) * 2003-02-05 2011-03-03 David Benn Lovejoy Metallionenchelatoren und ihre therapeutische verwendung
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
AU2005306772A1 (en) * 2004-11-19 2006-05-26 Shiva Biomedical, Llc Methods of treating erythropoietin-resistance
KR101208587B1 (ko) 2009-06-24 2012-12-06 여오영 하이드록시클로로퀸을 포함하는 항암 치료를 위한 국소 투여용 주사제 조성물
DK2900667T3 (da) 2012-09-21 2019-08-26 Vivolux Ab Middel og fremgangsmåde til behandling af faste tumorer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002089809A1 (en) * 2001-05-04 2002-11-14 The Procter & Gamble Company Medicinal uses of hydrazones and hydrazines
WO2007128820A1 (en) * 2006-05-09 2007-11-15 Novartis Ag Combination comprising an iron chelator and an anti-neoplastic agent and use thereof
WO2009035534A2 (en) * 2007-09-07 2009-03-19 The Cleveland Clinic Foundation Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Pharmazie, 1987, vol. 42, pp. 664-666 *

Also Published As

Publication number Publication date
US10022380B2 (en) 2018-07-17
ZA201307036B (en) 2014-05-28
EP2688569A4 (en) 2014-09-10
WO2012128689A1 (en) 2012-09-27
SG10201605083SA (en) 2016-08-30
ES2681703T3 (es) 2018-09-14
KR20140017619A (ko) 2014-02-11
SG193494A1 (en) 2013-10-30
CA2830081A1 (en) 2012-09-27
EP2688569B1 (en) 2018-05-30
US20170348317A1 (en) 2017-12-07
CN103547268A (zh) 2014-01-29
AU2012231814A1 (en) 2013-09-26
IL228411A (en) 2016-12-29
KR101937279B1 (ko) 2019-01-10
PL2688569T3 (pl) 2018-09-28
DK2688569T3 (en) 2018-08-06
MX2013010770A (es) 2014-03-27
BR112013024211A2 (pt) 2016-12-20
JP6064215B2 (ja) 2017-02-01
US20140073645A1 (en) 2014-03-13
PT2688569T (pt) 2018-08-06
IL228411A0 (en) 2013-12-31
BR112013024211B1 (pt) 2020-12-15
CN103547268B (zh) 2017-02-22
EP2688569A1 (en) 2014-01-29
JP2014508804A (ja) 2014-04-10
TR201809040T4 (tr) 2018-07-23
EA201391286A1 (ru) 2014-03-31
CA2830081C (en) 2020-09-22
EA025180B1 (ru) 2016-11-30
HUE039021T2 (hu) 2018-12-28

Similar Documents

Publication Publication Date Title
AU2012231814B2 (en) Treatment of solid tumours
Islam et al. Eugenol potentiates cisplatin anti‐cancer activity through inhibition of ALDH‐positive breast cancer stem cells and the NF‐κB signaling pathway
Harhaji‐Trajkovic et al. AMPK‐mediated autophagy inhibits apoptosis in cisplatin‐treated tumour cells
Pei et al. 6-Shogaol from ginger shows anti-tumor effect in cervical carcinoma via PI3K/Akt/mTOR pathway
Li et al. A novel HDAC6 inhibitor Tubastatin A: Controls HDAC6-p97/VCP-mediated ubiquitination-autophagy turnover and reverses Temozolomide-induced ER stress-tolerance in GBM cells
Wu et al. UCN-01 induces S and G2/M cell cycle arrest through the p53/p21waf1or CHK2/CDC25C pathways and can suppress invasion in human hepatoma cell lines
Wang et al. Synthesis of improved lysomotropic autophagy inhibitors
Ye et al. Anti-tumor activity and relative mechanism of ethanolic extract of Marsdenia tenacissima (Asclepiadaceae) against human hematologic neoplasm in vitro and in vivo
Zheng et al. Metapristone suppresses non-small cell lung cancer proliferation and metastasis via modulating RAS/RAF/MEK/MAPK signaling pathway
JP6101827B2 (ja) がん幹細胞の増殖抑制剤および細胞内活性酸素蓄積誘導剤
Kinzel et al. A novel HSP90 inhibitor with reduced hepatotoxicity synergizes with radiotherapy to induce apoptosis, abrogate clonogenic survival, and improve tumor control in models of colorectal cancer
Muscella et al. The platinum (II) complex [Pt (O, O′-acac)(γ-acac)(DMS)] alters the intracellular calcium homeostasis in MCF-7 breast cancer cells
Yan et al. The targeted inhibition of mitochondrial Hsp90 overcomes the apoptosis resistance conferred by Bcl-2 in Hep3B cells via necroptosis
Zhu et al. Mechanisms of autophagy and endoplasmic reticulum stress in the reversal of platinum resistance of epithelial ovarian cancer cells by naringin
Beberok et al. The role of MITF and Mcl-1 proteins in the antiproliferative and proapoptotic effect of ciprofloxacin in amelanotic melanoma cells: In silico and in vitro study
Liu et al. Maackiain dampens osteoclastogenesis via attenuating RANKL‐stimulated NF‐κB signalling pathway and NFATc1 activity
US8637679B2 (en) Process for the isolation of organic compounds useful for the treatment of cancer
Gonzaga et al. A novel triazole derivative drug presenting in vitro and in vivo anticancer properties
Goldberg et al. 3, 3′-Diindolylmethane (DIM) and its ring-substituted halogenated analogs (ring-DIMs) induce differential mechanisms of survival and death in androgen-dependent and–independent prostate cancer cells
Ling et al. Identification of substituted 5-membered heterocyclic compounds as potential anti-leukemic agents
Liu et al. New 1, 1-diarylethylene FOXM1 inhibitors potently reduce intracellular FOXM1 and suppress high-grade serous ovarian carcinoma cell viability
HK1191561A (en) Treatment of solid tumours
HK1191561B (en) Treatment of solid tumours
KR100812032B1 (ko) 3,4-디히드로이소퀴놀리늄 염 유도체를 포함하는 항암제
RU2429839C1 (ru) Средство, предотвращающее трансформацию нормальных клеток млекопитающих в опухолевые

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)